Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mariko Yabe

Showing results (31-40 of 53) with videos related to

Pageof 6
Sort By:
British Journal of Haematology|July 3, 2023
Outcomes after interruption of targeted therapy in patients with histiocytic neoplasmsAnne S Reiner, Benjamin H Durham, Mariko Yabe, et al.
The American Journal of Surgical Pathology|March 3, 2020
Genetic Basis of Extramedullary Plasmablastic Transformation of Multiple MyelomaYing Liu, Fatima Jelloul, Yanming Zhang, et al.
JCO Precision Oncology|November 9, 2020
Aggressive Hematopoietic Malignancy Characterized by Biallelic Loss of <i>SMARCB1</i>Michael D Kinnaman, Darcy Hamill, Mariko Yabe, et al.
American Journal of Hematology|September 13, 2008
Multicenter prospective trial evaluating the tolerability of imatinib for Japanese patients with chronic myelogenous leukemia in the chronic phase: does body weight matter?Yoshinobu Kanda, Shinichiro Okamoto, Tetsuzo Tauchi, et al.
Neuro-Oncology|January 18, 2020
Neurologic and oncologic features of Erdheim-Chester disease: a 30-patient seriesAnkush Bhatia, Vaios Hatzoglou, Gary Ulaner, et al.
British Journal of Haematology|July 1, 2015
TP53 overexpression is an independent adverse prognostic factor in de novo myelodysplastic syndromes with fibrosisSanam Loghavi, Alyaa Al-Ibraheemi, Zhuang Zuo, et al.
Haematologica|April 18, 2020
Myeloid/lymphoid neoplasms with eosinophilia/ basophilia and ETV6-ABL1 fusion: cell-of-origin and response to tyrosine kinase inhibitionJinJuan Yao, Lianrong Xu, Umut Aypar, et al.
Leukemia|November 8, 2024
The effect of methylation on the let-7-BCL2L1-BCL2 axis and the potential use of hypomethylating and BH3 mimetic drugs in histiocytic neoplasmsMali Salmon-Divon, Refael Meyuchas, Ofer Shpilberg, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|August 7, 2016
Donor-Derived T-Cell Large Granular Lymphocytic Leukemia in a Patient With Peripheral T-Cell LymphomaJuliana E Hidalgo Lopez, Mariko Yabe, Adrian A Carballo-Zarate, et al.
Blood Advances|October 24, 2023
Mutant PIK3CA is a targetable driver alteration in histiocytic neoplasmsBenjamin H Durham, Oshrat Hershkovitz-Rokah, Omar Abdel-Wahab, et al.
Pageof 6

Showing results (31-40 of 53) with videos related to

Sort By:
Pageof 6
British Journal of Haematology|July 3, 2023
Outcomes after interruption of targeted therapy in patients with histiocytic neoplasmsAnne S Reiner, Benjamin H Durham, Mariko Yabe, et al.
The American Journal of Surgical Pathology|March 3, 2020
Genetic Basis of Extramedullary Plasmablastic Transformation of Multiple MyelomaYing Liu, Fatima Jelloul, Yanming Zhang, et al.
JCO Precision Oncology|November 9, 2020
Aggressive Hematopoietic Malignancy Characterized by Biallelic Loss of <i>SMARCB1</i>Michael D Kinnaman, Darcy Hamill, Mariko Yabe, et al.
American Journal of Hematology|September 13, 2008
Multicenter prospective trial evaluating the tolerability of imatinib for Japanese patients with chronic myelogenous leukemia in the chronic phase: does body weight matter?Yoshinobu Kanda, Shinichiro Okamoto, Tetsuzo Tauchi, et al.
Neuro-Oncology|January 18, 2020
Neurologic and oncologic features of Erdheim-Chester disease: a 30-patient seriesAnkush Bhatia, Vaios Hatzoglou, Gary Ulaner, et al.
British Journal of Haematology|July 1, 2015
TP53 overexpression is an independent adverse prognostic factor in de novo myelodysplastic syndromes with fibrosisSanam Loghavi, Alyaa Al-Ibraheemi, Zhuang Zuo, et al.
Haematologica|April 18, 2020
Myeloid/lymphoid neoplasms with eosinophilia/ basophilia and ETV6-ABL1 fusion: cell-of-origin and response to tyrosine kinase inhibitionJinJuan Yao, Lianrong Xu, Umut Aypar, et al.
Leukemia|November 8, 2024
The effect of methylation on the let-7-BCL2L1-BCL2 axis and the potential use of hypomethylating and BH3 mimetic drugs in histiocytic neoplasmsMali Salmon-Divon, Refael Meyuchas, Ofer Shpilberg, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|August 7, 2016
Donor-Derived T-Cell Large Granular Lymphocytic Leukemia in a Patient With Peripheral T-Cell LymphomaJuliana E Hidalgo Lopez, Mariko Yabe, Adrian A Carballo-Zarate, et al.
Blood Advances|October 24, 2023
Mutant PIK3CA is a targetable driver alteration in histiocytic neoplasmsBenjamin H Durham, Oshrat Hershkovitz-Rokah, Omar Abdel-Wahab, et al.
Pageof 6